CVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CVS is a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is in an established uptrend, Wall Street sentiment is broadly positive with multiple recent target hikes, Congress trading data is bullish, and recent GLP-1 expansion news adds a clear catalyst. The main drawback is that the stock is technically overbought in the short term, so the ideal move would normally be to wait for a pullback; however, since the user wants an immediate, direct call and is not interested in waiting for a better entry, the current setup still supports buying, though more as a long-term accumulation than a short-term trade.
CVS is trading at 104.7, near its recent resistance zone (R1 104.032 and R2 105.882) after a strong regular-session move of 2.74%. The trend is bullish: SMA_5 is above SMA_20 and SMA_200, and MACD histogram is positive and expanding, which supports upward momentum. RSI_6 at 80.213 shows the stock is overbought, so near-term upside may be choppy, but the overall trend remains constructive. The pivot at 101.037 now acts as an important support reference, with 98.042 as the next major support.
["Recent GLP-1 support program expansion across 9,000 pharmacy locations, MinuteClinic, and virtual platform", "Stock reacted positively to the GLP-1 expansion news with a 3% move", "Strong analyst target increases and repeated Buy/Overweight ratings", "Congress members have made 3 purchase transactions and no sales in the last 90 days", "Bullish technical trend with MACD expansion and moving-average alignment"]
["RSI is overbought, which raises the chance of short-term consolidation", "Florida Attorney General antitrust investigation into CVS Health", "Insiders have been selling, with selling amount up 1069.69% over the last month", "No clear Intellectia AI Stock Picker or SwingMax signal today"]
No usable latest-quarter financial snapshot was provided because the financial snapshot data returned an error. Based on the available analyst commentary, the latest quarter appears to have been solid, with favorable Q1 medical cost trends, improving government business margins, and constructive commercial business performance. The market is also treating management's 2026 guidance as conservative, which suggests earnings expectations may still have room to rise. The latest quarter season referenced by analysts is Q1 2026.
Wall Street remains constructive. Recent notes show a clear upward trend in price targets: BofA to $110, Morgan Stanley to $111, Truist to $108, Barclays to $106, Mizuho to $110, JPMorgan to $111, TD Cowen to $110, and Wells Fargo to $103, with ratings largely Buy, Overweight, or Outperform. The pros view CVS as benefiting from Medicare Advantage turnaround potential, PBM reform clarity, margin recovery, and possible earnings upside. The main con is that some upside may already be partially reflected after the recent multiple expansion and strong run.
